Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability.

Guloksuz S, Wichers M, Kenis G, Russel MG, Wauters A, Verkerk R, Arts B, van Os J.

PLoS One. 2013;8(3):e60435. doi: 10.1371/journal.pone.0060435. Epub 2013 Mar 27.

2.

[Anti-TNF therapy in treatment of luminal Crohn's disease].

Marko B, Prka L.

Acta Med Croatica. 2013 Apr;67(2):179-89. Review. Croatian.

PMID:
24471301
3.

Optimising monitoring in the management of Crohn's disease: a physician's perspective.

Papay P, Ignjatovic A, Karmiris K, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF, Panaccione R.

J Crohns Colitis. 2013 Sep;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005. Epub 2013 Apr 4. Review.

4.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
5.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
6.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

Supplemental Content

Support Center